Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board

Inhibitors of the sodium-glucose cotransporter type 2 (SGLT2i) are a modern class of antihyperglycemic drugs with an insulin-independent mechanism of action. Due to its ability to effectively lower blood glucose levels, improve a number of other cardiometabolic parameters (body weight, blood pressure, uric acid), as well as reduce cardiovascular and renal risks, SGLT2i have become drugs of choice for many of patients with type 2 diabetes mellitus (T2DM). Meanwhile, along with the generally recognized classes-effects of this group of drugs, there are intragroup features, including those associated with their different selectivity in sodium-glucose cotransporters of types 1 and 2 (SGLT1 and SGLT 2). For example, one of the most studied SGLT2i, canagliflozin, in addition to its inhibitory activity against SGLT2, can also moderately block SGLT1 in the intestine and kidneys that could give a maximum efficiency in the control glycemia and others cardiometabolic parameters. In addition, canagliflozin improves not only cardiovascular, but also renal prognosis in patients with T2DM, which is reflected in the corresponding indications in the summary of product characteristics of the drug. This document summarize the established and new data regarding the efficacy and safety of canagliflozin, as well as its place in the treatment of T2DM.

1. Инструкция по применению лекарственного препарата для медицинского применения Инвокана® ЛП-002977. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7e19c450-bd8a-4fa4-a9f1-f789b8515544&t=)

2. Ohgaki R, Wei L, Yamada K, et al. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther. 2016;358(1):94-102. doi: https://doi.org/10.1124/jpet.116.232025

3. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154-2161. doi: https://doi.org/10.2337/dc12-2391

4. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382. doi: https://doi.org/10.1111/dom.12054

5. Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015;17(2):188-197. doi: https://doi.org/10.1111/dom.12418

6. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl. 2007;(106):S27-S35. doi: https://doi.org/10.1038/sj.ki.5002383

7. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427-3434. doi: https://doi.org/10.2337/diabetes.54.12.3427

8. Yakovleva T, Sokolov V, Chu L, et al. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes Obes Metab. 2019;21(12):2684-2693. doi: https://doi.org/10.1111/dom.13858

9. Sokolov V, Yakovleva T, Chu L, et al. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. CPT Pharmacometrics Syst Pharmacol. 2020;9(4):222-229. doi: https://doi.org/10.1002/psp4.12498

10. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-885. doi: https://doi.org/10.2337/diacare.26.3.881

11. DECODE Study Group, the European Diabetes Epidemiology Group.. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161(3):397-405. doi: https://doi.org/10.1001/archinte.161.3.397

12. Wilding JP, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications. 2015;29(3):438-444. doi: https://doi.org/10.1016/j.jdiacomp.2014.12.016

13. Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014;14:37. Published 2014 Apr 18. doi: https://doi.org/10.1186/1472-6823-14-37

14. Merton K, Davies MJ, Vijapurkar U, et al. Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes. Curr Med Res Opin. 2018;34(2):313-318. doi: https://doi.org/10.1080/03007995.2017.1391759

15. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. 9th edition. Diabetes mellitus. 2019;22(1S1):1-144. (In Russ.). doi: https://doi.org/10.14341/DM221S1

16. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941-950. doi: https://doi.org/10.1016/S0140-6736(13)60683-2

17. Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355-364. doi: https://doi.org/10.2337/dc13-2762

18. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582-2592. doi: https://doi.org/10.1007/s00125-013-3039-1

19. Wysham CH, Lefebvre P, Pilon D, et al. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. J Diabetes Complications. 2019;33(2):140-147. doi: https://doi.org/10.1016/j.jdiacomp.2018.10.016

20. Blonde L, Patel C, Bookhart B, et al. A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin. Curr Med Res Opin. 2018;34(6):1143-1152. doi: https://doi.org/10.1080/03007995.2018.1458709

21. Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783-794. doi: https://doi.org/10.1111/dom.12670

22. Li JW, Badve CV, Zhou Z, et. al. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatol. 2019;1:e220-228. doi: https://doi.org/10.1016/S2665-9913(19)30078-5

23. Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(4):812-821. doi: https://doi.org/10.1111/dom.13584

24. Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2099. doi: https://doi.org/10.1056/NEJMc1712572

25. Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018;20(11):2585-2597. doi: https://doi.org/10.1111/dom.13424

26. Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415. doi: https://doi.org/10.1186/1756-0500-7-415

27. Go AS, Yang J, Tan TC, et al. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus. BMC Nephrol. 2018;19(1):146. doi: https://doi.org/10.1186/s12882-018-0942-1

28. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733. doi: https://doi.org/10.1016/S0140-6736(20)30045-3

29. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869. doi: https://doi.org/10.1056/NEJMoa011161

30. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860. doi: https://doi.org/10.1056/NEJMoa011303

31. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761-772. doi: https://doi.org/10.1038/s41569-020-0406-8

32. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi: https://doi.org/10.1056/NEJMoa1811744

33. Durkin M, Blais J. Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy. Diabetes Ther. 2021;12(2):499-508. doi: https://doi.org/10.1007/s13300-020-00953-4

34. INVOKANA® prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204042s034lbl.pdf

35. Usiskin K, Kline I, Fung A, et al. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014;126(3):16-34. doi: https://doi.org/10.3810/pgm.2014.05.2753

36. Engelhardt K, Ferguson M, Rosselli JL. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors. Ann Pharmacother. 2021;55(4):543-548. doi: https://doi.org/10.1177/1060028020951928

37. Matthews DR, Li Q, Perkovic V, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia. 2019;62(6):926-938. doi: https://doi.org/10.1007/s00125-019-4839-8

38. FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin

39. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111-S124. doi: https://doi.org/10.2337/dc21-S009

40. CDC. National Diabetes Statistics Report 2020. Available from: https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html

41. Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. Diabetes Care. 2018;41(1):e4-e5. doi: https://doi.org/10.2337/dc17-1551

42. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425-1435. doi: https://doi.org/10.1056/NEJMoa2004967

43. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [published correction appears in Lancet. 2019 Jan 5;393(10166):30]. Lancet. 2019;393(10166):31-39. doi: https://doi.org/10.1016/S0140-6736(18)32590-X

44. Cai J, Divino V, Burudpakdee C. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States. Curr Med Res Opin. 2017;33(7):1317-1328. doi: https://doi.org/10.1080/03007995.2017.1320277.